Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Tonix Pharma ( (TNXP) ) has shared an announcement.
Tonix Pharmaceuticals announced that the FDA has set a Prescription Drug User Fee Act goal date of August 15, 2025, for its decision on the marketing approval of TNX-102 SL, a product candidate aimed at managing fibromyalgia. This milestone could significantly impact Tonix’s market positioning and influence stakeholder expectations within the pharmaceutical industry.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on developing therapeutics for central nervous system disorders, immunology, and infectious diseases.
YTD Price Performance: -95.26%
Average Trading Volume: 92,057,839
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $114.3M
See more insights into TNXP stock on TipRanks’ Stock Analysis page.
